Sandoz, the generic and biosimilar medicines business of Swiss pharma giant Novartis (NOVN: VX), has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine (micafungin sodium, trade named Funguard in Japan) from Astellas Pharma (TYO: 4503).
The deal is expected to close in the course of first-half 2023, subject to standard conditions and regulatory approvals.
Astellas reported Mycamine sales of 18.9 billion yen ($135 million) for the year ending March 31, 2022. The announcement comes after Sandoz, which Novartis plans to split out as a separate company, successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze